Table 2.
Comparison of treatment, PROs and incident knee surgery between GLP-1RA and non-GLP-1RA groups
| GLP-1RA (n=233) | Non-GLP-1RA (n=1574) | Adjusted mean difference* (95% CI) | P value | Adjusted P value* | |
| Weight, kg | |||||
| At last follow-up | 61.4 (14.0) | 67.8 (13.6) | - | <0.001 | - |
| Change from baseline | −4.60 (8.07) | 2.69 (5.23) | −7.29 (−8.07, −6.50) | <0.001 | <0.001 |
| HbA1c, % | |||||
| At last follow-up | 7.3 (1.5) | 7.3 (1.6) | - | 0.79 | - |
| Change from baseline | 0.02 (1.26) | 0.08 (1.23) | −0.05 (−0.22, 0.12) | 0.53 | 0.56 |
| WOMAC total score | |||||
| At last follow-up | 21.9 (10.3) | 23.4 (10.0) | - | 0.039 | - |
| Change from baseline | 2.65 (14.17) | 3.58 (13.99) | −1.46 (−2.84, −0.08) | 0.35 | 0.038 |
| WOMAC pain subscore | |||||
| At last follow-up | 17.1 (12.6) | 19.4 (12.5) | - | 0.010 | - |
| Change from baseline | −1.18 (19.00) | 2.01 (17.60) | −3.37 (−5.79, −0.94) | 0.011 | 0.007 |
| WOMAC stiffness subscore | |||||
| At last follow-up | 24.0 (15.8) | 24.7 (15.8) | - | 0.54 | - |
| Change from baseline | 5.79 (21.08) | 6.33 (20.43) | −1.05 (−3.35, 1.25) | 0.71 | 0.37 |
| WOMAC function subscore | |||||
| At last follow-up | 23.1 (12.3) | 24.4 (12.3) | - | 0.13 | - |
| Change from baseline | 3.41 (17.65) | 3.72 (17.25) | −0.95 (−2.71, 0.81) | 0.80 | 0.29 |
| Annual consumption of oral NSAIDs and acetaminophen, RDD/year | 15.2 (13.8) | 16.9 (14.5) | −1.63 (−3.62, 0.36) | 0.10 | 0.11 |
| Annual consumption of topical NSAIDs, RDD/year | 21.7 (22.7) | 23.6 (22.8) | −1.92 (−5.06, 1.21) | 0.22 | 0.23 |
| Annual consumption of opioids, MME/year | 109.0 (190.0) | 126.2 (205.6) | −17.07 (−45.09, 10.94) | 0.20 | 0.23 |
| Total no of intra-articular therapies | 7.5 (13.4) | 9.7 (15.3) | - | 0.022 | - |
| Annual no of intra-articular therapies, per year | 1.07 (1.99) | 1.30 (2.12) | −0.24 (−0.53, 0.05) | 0.10 | 0.10 |
| Annual no of intra-articular injection of steroids, per year | 0.13 (0.28) | 0.22 (0.39) | −0.087 (−0.14, − 0.036) | <0.001 | 0.001 |
| Follow-up, years | 7.7 (1.5) | 7.8 (1.6) | - | 0.71 | - |
| Knee surgery | 4 (1.7%) | 93 (5.9%) | - | 0.005 | 0.014 |
Data are shown as means (SDs) unless otherwise indicated.
WOMAC questionnaire and all its subscales were normalised to scores within a range of 0–100.
*Mean difference and p value adjusted for age, sex, baseline BMI, baseline Kellgren-Lawrence grade and baseline WOMAC total score.
GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, hemoglobin A1c; MME, milligram morphine equivalents; NSAIDs, non-steroidal anti-inflammatory drugs; PROs, patient-reported outcomes; RDD, recommended daily dose; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.